These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

327 related items for PubMed ID: 25055137

  • 1. High frequency and clinical prognostic value of MYD88 L265P mutation in primary cutaneous diffuse large B-cell lymphoma, leg-type.
    Pham-Ledard A, Beylot-Barry M, Barbe C, Leduc M, Petrella T, Vergier B, Martinez F, Cappellen D, Merlio JP, Grange F.
    JAMA Dermatol; 2014 Nov; 150(11):1173-9. PubMed ID: 25055137
    [Abstract] [Full Text] [Related]

  • 2. Improvement of survival in patients with primary cutaneous diffuse large B-cell lymphoma, leg type, in France.
    Grange F, Joly P, Barbe C, Bagot M, Dalle S, Ingen-Housz-Oro S, Maubec E, D'Incan M, Ram-Wolff C, Dalac S, Templier I, Esteve E, Quereux G, Machet L, Leduc M, Dereure O, Laroche L, Saiag P, Vergier B, Beylot-Barry M.
    JAMA Dermatol; 2014 May; 150(5):535-41. PubMed ID: 24647650
    [Abstract] [Full Text] [Related]

  • 3. Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases.
    Grange F, Beylot-Barry M, Courville P, Maubec E, Bagot M, Vergier B, Souteyrand P, Machet L, Dalac S, Esteve E, Templier I, Delaporte E, Avril MF, Robert C, Dalle S, Laroche L, Delaunay M, Joly P, Wechsler J, Petrella T.
    Arch Dermatol; 2007 Sep; 143(9):1144-50. PubMed ID: 17875875
    [Abstract] [Full Text] [Related]

  • 4. MYD88 expression and L265P mutation in diffuse large B-cell lymphoma.
    Choi JW, Kim Y, Lee JH, Kim YS.
    Hum Pathol; 2013 Jul; 44(7):1375-81. PubMed ID: 23380077
    [Abstract] [Full Text] [Related]

  • 5. Identification of Somatic Mutations in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type by Massive Parallel Sequencing.
    Mareschal S, Pham-Ledard A, Viailly PJ, Dubois S, Bertrand P, Maingonnat C, Fontanilles M, Bohers E, Ruminy P, Tournier I, Courville P, Lenormand B, Duval AB, Andrieu E, Verneuil L, Vergier B, Tilly H, Joly P, Frebourg T, Beylot-Barry M, Merlio JP, Jardin F.
    J Invest Dermatol; 2017 Sep; 137(9):1984-1994. PubMed ID: 28479318
    [Abstract] [Full Text] [Related]

  • 6. MyD88 Mutation in Elderly Predicts Poor Prognosis in Primary Central Nervous System Lymphoma: Multi-Institutional Analysis.
    Takano S, Hattori K, Ishikawa E, Narita Y, Iwadate Y, Yamaguchi F, Nagane M, Akimoto J, Oka H, Tanaka S, Sakata M, Matsuda M, Yamamoto T, Chiba S, Matsumura A.
    World Neurosurg; 2018 Apr; 112():e69-e73. PubMed ID: 29258950
    [Abstract] [Full Text] [Related]

  • 7. Frequent MYD88 L265P and CD79B Mutations in Primary Breast Diffuse Large B-Cell Lymphoma.
    Taniguchi K, Takata K, Chuang SS, Miyata-Takata T, Sato Y, Satou A, Hashimoto Y, Tamura M, Nagakita K, Ohnishi N, Noujima-Harada M, Tabata T, Kikuti YY, Maeda Y, Nakamura N, Tanimoto M, Yoshino T.
    Am J Surg Pathol; 2016 Mar; 40(3):324-34. PubMed ID: 26752547
    [Abstract] [Full Text] [Related]

  • 8. CD79B and MYD88 mutations in diffuse large B-cell lymphoma.
    Kim Y, Ju H, Kim DH, Yoo HY, Kim SJ, Kim WS, Ko YH.
    Hum Pathol; 2014 Mar; 45(3):556-64. PubMed ID: 24444466
    [Abstract] [Full Text] [Related]

  • 9. Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases.
    Dubois S, Viailly PJ, Bohers E, Bertrand P, Ruminy P, Marchand V, Maingonnat C, Mareschal S, Picquenot JM, Penther D, Jais JP, Tesson B, Peyrouze P, Figeac M, Desmots F, Fest T, Haioun C, Lamy T, Copie-Bergman C, Fabiani B, Delarue R, Peyrade F, André M, Ketterer N, Leroy K, Salles G, Molina TJ, Tilly H, Jardin F.
    Clin Cancer Res; 2017 May 01; 23(9):2232-2244. PubMed ID: 27923841
    [Abstract] [Full Text] [Related]

  • 10. MYD88 L265P mutation detected by digital PCR as a prognostic factor in patients with diffuse large B-cell lymphoma in rituximab era.
    Nishimura N, Takeuchi K, Asaka R, Tuyama N, Inoue N, Kusano Y, Mishima Y, Yokoyama M, Terui Y.
    Leuk Res; 2020 Oct 01; 97():106426. PubMed ID: 32781214
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. MYD88 expression and L265P mutation in mature B-cell non-Hodgkin lymphomas.
    Caner V, Sen Turk N, Baris IC, Cetin GO, Tepeli E, Hacioglu S, Sari I, Zencir S, Dogu MH, Bagci G, Keskin A.
    Genet Test Mol Biomarkers; 2015 Jul 01; 19(7):372-8. PubMed ID: 25978699
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. PREVALENCE OF MYD88 L265P MUTATION IN HISTOLOGICALLY PROVEN, DIFFUSE LARGE B-CELL VITREORETINAL LYMPHOMA.
    Raja H, Salomão DR, Viswanatha DS, Pulido JS.
    Retina; 2016 Mar 01; 36(3):624-8. PubMed ID: 26900675
    [Abstract] [Full Text] [Related]

  • 17. Clinicopathological features of 49 primary gastrointestinal diffuse large B-cell lymphoma cases; comparison with location, cell-of-origin, and frequency of MYD88 L265P.
    Nagakita K, Takata K, Taniguchi K, Miyata-Takata T, Sato Y, Tari A, Ohnishi N, Noujima-Harada M, Omote S, Nakamura N, Iwamuro M, Maeda Y, Okada H, Tanimoto M, Yoshino T.
    Pathol Int; 2016 Aug 01; 66(8):444-52. PubMed ID: 27439595
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Utility of clinical, laboratory, and lymph node MYD88 L265P mutation in risk assessment of diffuse large B-cell lymphoma patients.
    Hanbal AT, El-Ashwah S, Eladl AE, Shamaa S, Saleh LM.
    J Egypt Natl Canc Inst; 2024 Oct 14; 36(1):31. PubMed ID: 39397180
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.